3M & PFAS Contamination: A Comprehensive Timeline & Settlement Overview

This page provides an essential timeline and comprehensive overview of the ongoing PFAS contamination litigation, EPA regulations, and related settlements, including 3M’s landmark $7.35 billion personal injury deal and major state environmental resolutions. We update this page regularly as new legal developments unfold, so be sure to bookmark it for the latest news.

• • November 3, 2026 – 3M Reaches $7.35 Billion Settlement Resolution for AFFF Personal Injury Claims

    • 3M Co. announced a landmark agreement to pay up to $7.35 billion over nine years to resolve approximately 99% of personal injury claims involving its per- and polyfluoroalkyl substances (PFAS) contained in aqueous film-forming foam (AFFF). Covering an estimated 115,000 to 120,000 plaintiffs both within and outside the South Carolina AFFF multidistrict litigation (MDL No. 2873), the deal establishes compensation pathways for six qualifying medical injuries, including kidney and testicular cancers.

  • August 4, 2025 – New Jersey Secures $2 Billion Settlement with DuPont

    • New Jersey Attorney General Matthew Platkin and Department of Environmental Protection Commissioner Shawn LaTourette announced a landmark $2B settlement with E.I. du Pont de Nemours to resolve PFAS contamination at several locations in the state. The agreement includes an $875m settlement in natural resources damages and a commitment from DuPont to fund abatement projects and full clean-up of impacted sites.

  • June 22, 2023 – 3M Agrees to $10.3B–$12.5B Public Water System Settlement

    • 3M reaches a settlement agreement between $10.3 billion to $12.5 billion with cities, towns, and public water systems for PFAS contamination in municipal drinking water.

  • March 2023 – EPA Proposes National Drinking Water Standards

    • The EPA proposed the first national drinking water standards for PFOA and PFOS and announced its intention to regulate additional PFAS.

  • June 15, 2022 – EPA Issues Stricter Health Advisories

    • The EPA issued revised, stricter health advisories for PFAS, indicating effectively no safe level for PFOA and PFOS.

  • Recent Years – Nationwide Awareness and Expanded Litigation

    • Increasing public awareness and continued litigation of PFAS contamination across the U.S. continue to target consumer goods, industrial sites, and water providers.

  • March 2, 2021 – 3M Motions to Transfer Michigan State Litigation

    • 3M argued in Michigan federal court that a PFAS lawsuit should be moved from state to federal court.

  • January 22, 2021 – DuPont, Corteva, and Chemours Commit $1.185B for Liabilities

    • DuPont, Corteva, and Chemours committed $1.185 billion to resolve PFAS liabilities and $83 million to settle Ohio MDL claims.

  • September 11, 2020 – Hopatcong Borough Files Federal Suit Against 3M

    • Hopatcong Borough, NJ, filed a federal lawsuit against 3M for public water contamination.

  • 2020 – 3M Announces Manufacturing Phase-Out

    • 3M announces its intent to end PFOA and PFOS manufacturing by the end of 2025.

  • January 2020 – Michigan AG Files Suit Against 17 Defendants

    • The Michigan Attorney General filed a PFA contamination lawsuit against 17 defendants, including 3M.

  • 2017 – DuPont Settles Personal Injury MDL Claims for $670 Million

    • PFA MDL litigation involving 3,550 plaintiffs with personal injury claims against DuPont was settled for $670 million.

  • 2016 – EPA Issues Initial Health Advisories

    • The EPA issued initial health advisories for PFOA and PFOS, setting a combined limit of 70 parts per trillion (ppt).

  • 2015 – Chemours Spun Off from DuPont

    • Chemours was spun off from E.I. DuPont de Nemours and Co. to assume fluoropolymer chemical liabilities.

  • 2012 – Epidemiological Study Links PFAS to Six Medical Conditions

    • An EPA epidemiological study linked PFAS exposure to six core diseases in residents near DuPont’s Washington Works plant.

  • 2006 – Voluntary Phase-Out Agreement Established

    • A voluntary agreement between the EPA and major companies led to the phase-out of PFAS in U.S. manufacturing.

  • 2005 – DuPont Settles EPA Complaint & Medical Monitoring Class Action

    • DuPont reaches a $16.5 million settlement with the EPA for environmental violations and settled the 2001 class action for up to $235 million for medical monitoring.

  • 2001 – First Major Class Action Filed Against DuPont

    • A class action lawsuit is filed against DuPont on behalf of 70,000 residents near the Washington Works plant.

  • 1998 – Initial Toxic Tort Litigation Commences

    • Litigation begins with a lawsuit against DuPont for cattle losses near a PFOA-contaminated landfill.

  • Early Years – Commercial Product Integration

    • PFAS were incorporated into consumer products like Teflon, Scotchgard, firefighting foams, and waterproof clothing.

  • 1940s – Introduction of Fluorinated Chemistry

    • PFAS chemicals were first introduced and used in various consumer and industrial products.

Note on Ongoing Updates: As personal injury claim reviews, municipal distributions, and AFFF trial dockets advance, our mass tort analysts continually update this page. Law firms tracking regional water data can also cross-reference the expanding scope of forever chemical pollution across the U.S. to evaluate municipal exposure.

3M’s $7.35 Billion Personal Injury Settlement: Claim Readiness & Inventory Preparation

The November 2026 agreement by 3M to allocate up to $7.35 billion over nine years marks a pivotal turning point in AFFF mass tort litigation. Designed to resolve roughly 99% of personal injury claims across 115,000 to 120,000 plaintiffs, the settlement establishes specific compensation tiers for six qualifying conditions:

• Kidney Cancer

• Testicular Cancer

• Thyroid Disease

• Ulcerative Colitis

• Liver Cancer

• High Cholesterol / Hypercholesterolemia

With claims against remaining co-defendants proceeding in court and strict court-ordered evidentiary submission deadlines approaching, plaintiff law firms must ensure immediate inventory readiness. Successful settlement allocation depends on:

1. Structured Exposure Verification: Documenting occupational exposure histories, military service records (DD-214), and municipal firefighting usage logs.

2. Medical Record Integration: Gathering, indexing, and verifying diagnostic pathology reports for target cancers and severe conditions.

3. PFS Defect Management: Resolving data discrepancies across Plaintiff Fact Sheets to eliminate deficiency notices prior to fund distribution.

A Patchwork of Regulation and Risk

The lack of regulatory uniformity across states challenges legal teams. While federal agencies apply foundational statutes like the Safe Drinking Water Act, Clean Water Act, and Clean Air Act, state-level standards vary widely. This fragmented compliance landscape requires law firms to maintain nimble, data-driven case management workflows.

AFFF Litigation and Medical Proof

With major personal injury settlements taking shape, the scientific underpinnings of toxic exposure remain paramount. Court rulings continue to emphasize rigorous epidemiology linking fluorosurfactant exposure to specific health outcomes, making verified medical review and record collection vital for maintaining claim eligibility.

Mass Tort Expansion and Consumer Protection

As public awareness grows and federal regulatory standards tighten, plaintiffs’ law firms are seeing elevated mass tort potential. The intersection of environmental justice, consumer deceptive practices, and bodily injury claims creates complex administrative burdens for legal teams managing multi-thousand-claim inventories.

Navigating multi-billion-dollar PFAS settlement frameworks requires specialized operational infrastructure. Law firms managing high-volume AFFF or consumer toxic tort dockets rely on Verus to deliver defensible, scalable processes from client intake through fund distribution.

Verus delivers end-to-end support for leading mass tort law firms:

• PFAS Intake & Exposure Validation: Streamline client onboarding with customized eligibility screeners and exposure verification protocols.

• Medical Record Retrieval & Review: Systematically collect, index, and audit medical records to substantiate qualifying oncology and medical diagnoses.

• Plaintiff Fact Sheet (PFS) Processing: Eliminate evidentiary gaps and deficiency notices using automated QA data reconciliation.

• Settlement & Fund Administration Services: Administer complex Qualified Settlement Funds (QSF), calculate multi-tier allocations, and manage disbursements under court-approved frameworks.

• Advanced Analytics & Portfolio Modeling: Evaluate claimant inventories, project recovery values, and optimize trial team resource allocation.

To evaluate whether your firm’s AFFF and PFAS claim inventory is ready for upcoming settlement deadlines, explore our specialized mass tort litigation support solutions or contact the Verus team today.

Contact Verus today to learn how our data-driven approach can empower your firm to succeed in PFAS mass tort litigation.

Verus is an independent litigation support firm and is not directly affiliated with 3M, DuPont, or the AFFF MDL settlement administration program. This article is provided for informational and educational purposes for legal professionals.